Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Surgery Radical Cystectomy Clear all
Recruiting Phase 3 Interventional

Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol

NCT03216525
View directory record Official record
Conditions
Bladder Cancer
Interventions
Alvimopan, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 24, 2026, 4:58 AM EDT
Active, not recruiting Not applicable Interventional Results available

Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)

NCT05696444
View directory record Official record
Conditions
Bladder Cancer, Prostate Cancer, Kidney Cancer, Pelvic Tumor, Interstitial Cystitis, Congenital Abnormalities, End Stage Renal Disease, Renal Tumor, Kidney Injury
Interventions
RAS Prostatectomy, RAS Cystectomy, RAS Nephrectomy
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
22 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
6
States / cities
Duarte, California • Chicago, Illinois • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 24, 2026, 4:58 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer

NCT03978624
View directory record Official record
Conditions
Bladder Cancer
Interventions
Pembrolizumab, Entinostat, Procedure/Surgery
Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 24, 2026, 4:58 AM EDT
Completed Phase 2 Interventional Results available

Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Transitional Cell Carcinoma of the Bladder

NCT00963859
View directory record Official record
Conditions
Bladder Cancer
Interventions
Robotic-assisted laparoscopic surgery
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Sep 24, 2026, 4:58 AM EDT
Recruiting Early Phase 1 Interventional

Virtual Histology of the Bladder Wall for Bladder Cancer Staging

NCT04369560
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Magnetic Resonance Imaging, Gadobutrol intravesical administration (4mM), Ferumoxytol intravesical administration (5 mM)
Diagnostic Test · Drug
Lead sponsor
Jodi Maranchie
Other
Eligibility
18 Years to 90 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 24, 2026, 4:58 AM EDT
Active, not recruiting Not applicable Interventional

Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder

NCT02968732
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Radical Cystectomy
Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 24, 2026, 4:58 AM EDT
Withdrawn Phase 3 Interventional

Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer

NCT02438852
View directory record Official record
Conditions
Bladder Carcinoma, Post-operative Pain
Interventions
Placebo, Questionnaire Administration, Ropivacaine Hydrochloride
Other · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 24, 2026, 4:58 AM EDT
Completed No phase listed Observational

Study of Outcomes After Surgery/Treatment to Treat Bladder Cancer

NCT01776138
View directory record Official record
Conditions
Bladder Cancer
Interventions
Collect Blood and Survey Instruments
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Sep 24, 2026, 4:58 AM EDT
Completed Phase 3 Interventional

A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy

NCT02145871
View directory record Official record
Conditions
Bladder Cancer
Interventions
standard fluid management, fluid management guided by the EV1000
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 24, 2026, 4:58 AM EDT
Terminated Phase 2 Interventional Results available

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

NCT05581589
View directory record Official record
Conditions
Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Lymphadenectomy, Radical Cystectomy, Sacituzumab Govitecan
Procedure · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 24, 2026, 4:58 AM EDT
Completed No phase listed Observational

Physical Therapy in Pre-cystectomy Patients

NCT05978570
View directory record Official record
Conditions
Bladder Cancer
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Sep 24, 2026, 4:58 AM EDT
Terminated Not applicable Interventional

Robotic or Open Radical Cystectomy in Treating Patients With Bladder Cancer

NCT02699853
View directory record Official record
Conditions
Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
Interventions
Questionnaire Administration, Radical Cystectomy
Other · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Sep 24, 2026, 4:58 AM EDT
Active, not recruiting Phase 2 Interventional

Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer

NCT05241340
View directory record Official record
Conditions
Urothelial Carcinoma Bladder
Interventions
Sasanlimab, Stereotactic Body Radiation Therapy, Radical Cystectomy + pelvic lymph node dissection + urinary diversion
Drug · Radiation · Procedure
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 24, 2026, 4:58 AM EDT
Recruiting Not applicable Interventional

Evaluating Safety and Efficacy of Prostate-sparing Radical Cystectomy

NCT05792722
View directory record Official record
Conditions
Bladder Cancer
Interventions
Prostate capsule-sparing radical cystectomy, Nerve sparing radical cystectomy
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 24, 2026, 4:58 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

NCT03924895
View directory record Official record
Conditions
Urinary Bladder Cancer, Muscle-invasive
Interventions
Pembrolizumab, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Enfortumab Vedotin
Drug · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
39
States / cities
Mobile, Alabama • Little Rock, Arkansas • Fullerton, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 24, 2026, 4:58 AM EDT
Not listed Not applicable Interventional

Use of Pedometer Following Radical Cystectomy

NCT04305730
View directory record Official record
Conditions
Bladder Cancer, Ileus, Narcotic Use
Interventions
Use of a pedometer following surgery, Standard of care
Behavioral
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Sep 24, 2026, 4:58 AM EDT
Completed Not applicable Interventional Results available

Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial

NCT01157676
View directory record Official record
Conditions
Bladder Cancer Requiring Cystectomy
Interventions
Open radical cystectomy, Robotic assisted radical cystectomy, DaVinci robot
Procedure · Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
16
States / cities
Phoenix, Arizona • Orange, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Sep 24, 2026, 4:58 AM EDT
Active, not recruiting No phase listed Observational Results available

CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer

NCT03933826
View directory record Official record
Conditions
Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
570 participants
Timeline
2019 – 2029
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 24, 2026, 4:58 AM EDT
Terminated Phase 2 Interventional Results available

Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer

NCT01611662
View directory record Official record
Conditions
Distal Urethral Cancer, Proximal Urethral Cancer, Squamous Cell Carcinoma of the Bladder, Stage II Bladder Cancer, Stage III Bladder Cancer, Urethral Cancer Associated With Invasive Bladder Cancer
Interventions
gemcitabine hydrochloride, cisplatin, therapeutic conventional surgery, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2019 · Synced Sep 24, 2026, 4:58 AM EDT
Recruiting No phase listed Observational

Measuring Surgical Recovery After Radical Cystectomy

NCT03193970
View directory record Official record
Conditions
Bladder Cancer
Interventions
Post-Operative Recovery Registry
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2034
U.S. locations
10
States / cities
Stanford, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 24, 2026, 4:58 AM EDT
Terminated Phase 2 Interventional Results available

Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery

NCT00268450
View directory record Official record
Conditions
Bladder Cancer
Interventions
bevacizumab, cisplatin, gemcitabine hydrochloride, paclitaxel, cysectomy
Biological · Drug · Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 120 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
4
States / cities
Charleston, South Carolina • Florence, South Carolina • Mt. Pleasant, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Sep 24, 2026, 4:58 AM EDT
Completed Early Phase 1 Interventional

Impact Advanced Recovery® for Radical Cystectomy (RC) Patients: a Pilot Study

NCT01868087
View directory record Official record
Conditions
Bladder Cancer, Radical Cystectomy, Urinary Bladder Neoplasms, Surgery
Interventions
Boost Plus®, Impact Advanced Recovery®
Dietary Supplement
Lead sponsor
Jill Hamilton-Reeves, PhD RD LD
Other
Eligibility
40 Years to 90 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 24, 2026, 4:58 AM EDT
Completed Phase 2 Interventional

Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium

NCT00080795
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
filgrastim, cisplatin, doxorubicin hydrochloride, gemcitabine hydrochloride, ifosfamide, conventional surgery, neoadjuvant therapy
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2012 · Synced Sep 24, 2026, 4:58 AM EDT
Terminated Phase 2 Interventional Results available

An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma

NCT04586244
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
retifanlimab, epacadostat, INCAGN02385, INCAGN02390
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Iowa City, Iowa • Cincinnati, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 24, 2026, 4:58 AM EDT